{"id":890481,"date":"2025-09-29T16:32:13","date_gmt":"2025-09-29T20:32:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/"},"modified":"2025-09-29T16:32:13","modified_gmt":"2025-09-29T20:32:13","slug":"shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/","title":{"rendered":"Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately  Lead Plaintiff Deadline is November 17, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, Sept.  29, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VJDgNr6vPTIcpBAP8uTaIAimdRTFzGoqx-iyVLMfSJswS9HEAe07lc4S-vAg1dAOhnAOpZiHturyvUVrx2uhfI34z8_hYOBxyBl7iPkyqHpeev6n5DjvVMFfrq0OQvzTZR6yIVWQq3Qc0FuiwB7AIzOPUnnIr3FSAJRd4uHCGFg=\" rel=\"nofollow\" target=\"_blank\">Wolf Haldenstein Adler Freeman &amp; Herz LLP<\/a> reminds securities class action lawsuit has been filed in the <strong>United States District Court for the Northern District of California<\/strong> on behalf of all individuals and entities who purchased or otherwise acquired <strong>Cytokinetics, Incorporated (NASDAQ: CYTK)<\/strong> (\u201cCytokinetics\u201d or the \u201cCompany\u201d) securities between <strong>December 27, 2023, and May 6, 2025<\/strong> (the \u201cClass Period\u201d).<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hDM85HKU3YHXF6IqVq7JH-c8ukUusxPOHnixcJW5htS7FpdJqg4SqH4Y2dRcNTLfuKZQCPBcA2Y4-mfk-fYcZsyq1cYyAadv1PrP1SmbcUM04Iyxx2CbIDXnPYATVz9GsAHspTEe0sunrb9-fx2SATrIQmVERefPXsHZHqwj46l-z0An_B6RgY8_JU0O4kG8mvDg0dsBUAez3x7OMmsS4w==\" rel=\"nofollow\" target=\"_blank\">PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION<\/a>\n      <\/p>\n<p align=\"center\">\n        <strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/strong><br \/>\n        <strong>Cytokinetics Securities Class Action Lawsuit Summary<\/strong>\n      <\/p>\n<p>\n        <strong>Allegations:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">Defendants made <strong>materially false and misleading statements<\/strong> about the timeline for the <strong>New Drug Application (NDA)<\/strong> submission and approval process for <strong>aficamten<\/strong>.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">Cytokinetics represented that FDA approval of the NDA for aficamten was expected in the <strong>second half of 2025<\/strong>, citing a <strong>September 26, 2025 PDUFA date<\/strong>.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">The Company allegedly <strong>failed to disclose material risks<\/strong>, particularly its failure to submit a required <strong>Risk Evaluation and Mitigation Strategy (REMS)<\/strong>, which could delay regulatory approval.\n<\/li>\n<\/ul>\n<p>\n        <strong>Key Date:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt\">Investors must contact the firm <strong>before November 17, 2025<\/strong>, to be considered for the <strong>lead plaintiff motion deadline<\/strong>.\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Why\u00a0<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VJDgNr6vPTIcpBAP8uTaIAimdRTFzGoqx-iyVLMfSJswS9HEAe07lc4S-vAg1dAOBhC9UPEp0-xIQFcOSRrh6nJ1xgdoiPzrywjRnJSIozHHmqhq6htoI5nISlSjxUEG-odUiAJmtSiUrBgty_gNgJJOnWpwqaWsS3YW5UKElwg=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>Wolf Haldenstein Adler Freeman &amp; Herz LLP?<\/strong><br \/>\n        <\/a>:<\/p>\n<p align=\"justify\">This illustrious <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Pf4y8Y-qS6J6wq1Jk4BBQw4fpPgW8tFPwNANykcRizQO94zV1LHB6pySjPvOzr5jn9FK-D-7fRp3pne5-u2nOY-_gbFVYrQb9ptPGnZA0UBFli8sjecufMaQzAq8UgAK\" rel=\"nofollow\" target=\"_blank\">firm<\/a>, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements.\u00a0The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wMrQfc-32ACsSdBZILMci31QqF_L7x7MA_tROwT-ni_ZtNzotgwrPbt0w5hyIiDQ8Bwgilxi_dy8zEs2CmOa-yLCBYAzYClWgMg4CMHkdOZqhs8h09CN-QNmuxp9Csqu\" rel=\"nofollow\" target=\"_blank\">law firm\u00a0<\/a>brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.<\/p>\n<p align=\"justify\">We encourage all investors who have been affected or have information that will assist in our investigation, to contact\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VJDgNr6vPTIcpBAP8uTaIAimdRTFzGoqx-iyVLMfSJswS9HEAe07lc4S-vAg1dAO7THuMhZ4EINhd1qrlo1u4AxBzcxa8y7L8Gd26nmcx-E_YLeBo45Mx9adqFV4VnjxsgAqxbZl38X4EBqXTvw53LQ16Qs8gKAFNWZ7zZEaptc=\" rel=\"nofollow\" target=\"_blank\">Wolf Haldenstein Adler Freeman &amp; Herz LLP<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Contact:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Phone:<\/strong>\u00a0(800) 575-0735 or (212) 545-4774<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Email:\u00a0<\/strong><br \/>\n          <a href=\"mailto:classmember@whafh.com\" rel=\"nofollow\" target=\"_blank\">classmember@whafh.com<\/a>\n        <\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>Contact Person:<\/strong>\u00a0<a href=\"mailto:gstone@whafh.com\" rel=\"nofollow\" target=\"_blank\">Gregory Stone, Director of Case and Financial Analysis<\/a><\/p>\n<\/li>\n<\/ul>\n<p>\n        <strong>Firm Website:<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a0qJtjSV91_0ypy66LR_XOuLjPzWw762GWbO5emDP9ktzBejsDDqzD30Eo6rDMZ3oap1RgdyFUh1BLuchNGIJICMghhbV9m3R27yDfYOxztL73jS-GcUjJggeNbthIf2EudOpggjQZxy0drIhGgeBLhbCuZ7b2PwZqfNNZE0S0g=\" rel=\"nofollow\" target=\"_blank\">\u00a0Wolf Haldenstein Adler Freeman &amp; Herz LLP<\/a>\n      <\/p>\n<p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzA1OSM3MTcwNjU0IzIwMTc2NzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjhiNjhkMzUtYWYxYy00ZWQ4LWE5ZDQtMGMxYTViYmFmZDY4LTEwMjkyNDItMjAyNS0wOS0yOS1lbg==\/tiny\/Wolf-Haldenstein-Adler-Freeman.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) &#8212; Wolf Haldenstein Adler Freeman &amp; Herz LLP reminds securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all individuals and entities who purchased or otherwise acquired Cytokinetics, Incorporated (NASDAQ: CYTK) (\u201cCytokinetics\u201d or the \u201cCompany\u201d) securities between December 27, 2023, and May 6, 2025 (the \u201cClass Period\u201d). PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cytokinetics Securities Class Action Lawsuit Summary Allegations: Defendants made materially false and misleading statements about the timeline for the New Drug Application (NDA) submission and approval process for aficamten. Cytokinetics represented that FDA approval of the NDA for aficamten was expected &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately  Lead Plaintiff Deadline is November 17, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-890481","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) &#8212; Wolf Haldenstein Adler Freeman &amp; Herz LLP reminds securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all individuals and entities who purchased or otherwise acquired Cytokinetics, Incorporated (NASDAQ: CYTK) (\u201cCytokinetics\u201d or the \u201cCompany\u201d) securities between December 27, 2023, and May 6, 2025 (the \u201cClass Period\u201d). PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cytokinetics Securities Class Action Lawsuit Summary Allegations: Defendants made materially false and misleading statements about the timeline for the New Drug Application (NDA) submission and approval process for aficamten. Cytokinetics represented that FDA approval of the NDA for aficamten was expected &hellip; Continue reading &quot;Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-29T20:32:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzA1OSM3MTcwNjU0IzIwMTc2NzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025\",\"datePublished\":\"2025-09-29T20:32:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\\\/\"},\"wordCount\":319,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNzA1OSM3MTcwNjU0IzIwMTc2NzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\\\/\",\"name\":\"Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNzA1OSM3MTcwNjU0IzIwMTc2NzI=\",\"datePublished\":\"2025-09-29T20:32:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNzA1OSM3MTcwNjU0IzIwMTc2NzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNzA1OSM3MTcwNjU0IzIwMTc2NzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/","og_locale":"en_US","og_type":"article","og_title":"Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025 - Market Newsdesk","og_description":"NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) &#8212; Wolf Haldenstein Adler Freeman &amp; Herz LLP reminds securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all individuals and entities who purchased or otherwise acquired Cytokinetics, Incorporated (NASDAQ: CYTK) (\u201cCytokinetics\u201d or the \u201cCompany\u201d) securities between December 27, 2023, and May 6, 2025 (the \u201cClass Period\u201d). PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cytokinetics Securities Class Action Lawsuit Summary Allegations: Defendants made materially false and misleading statements about the timeline for the New Drug Application (NDA) submission and approval process for aficamten. Cytokinetics represented that FDA approval of the NDA for aficamten was expected &hellip; Continue reading \"Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-29T20:32:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzA1OSM3MTcwNjU0IzIwMTc2NzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025","datePublished":"2025-09-29T20:32:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/"},"wordCount":319,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzA1OSM3MTcwNjU0IzIwMTc2NzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/","name":"Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzA1OSM3MTcwNjU0IzIwMTc2NzI=","datePublished":"2025-09-29T20:32:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzA1OSM3MTcwNjU0IzIwMTc2NzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzA1OSM3MTcwNjU0IzIwMTc2NzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-cytokinetics-incorporated-nasdaq-cytk-should-contact-wolf-haldenstein-immediately-lead-plaintiff-deadline-is-november-17-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/890481","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=890481"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/890481\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=890481"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=890481"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=890481"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}